RxDoctor Payments Data

Brent Huffman, MD

Neurology · Saint Louis, MONPI 1154367282

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $39,200 of the $50,932 with a category attached, or 77.0%. Lilly USA, LLC accounts for 81.2% of it on its own, with 53 other manufacturers making up the rest. 2025 is the largest year on record at $41,709, more than ten times the $765 reported in 2019.

$50,932in general payments, 2019–2025

Across 694 payments — averaging $73.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$41K
  • AbbVie$2K
  • Supernus Pharmaceuticals, Inc.$768
  • Pfizer$536
  • UCB, Inc.$483
  • Novartis$472
  • plus $5K from 48 others

What the payments were for

  • Speaking & faculty fees$39,20077%
  • Travel & lodging$1,1632%
  • Food & beverage$10,48421%
  • Education$850%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$50,932 in reported general payments places this provider in the 85th percentile of 381 neurology providers in Missouri.

See all neurology providers in Missouri →

Medicare billing

Part B allowed, 2024
$132,530
Medicare patients
552
Services billed
4,531

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate11$81,019
Emgality PenGalcanezumab-Gnlm91$62,067
Aimovig AutoinjectorErenumab-Aooe68$54,979
Nurtec OdtRimegepant Sulfate44$49,652
QuliptaAtogepant31$33,127
UbrelvyUbrogepant22$23,598
Ajovy SyringeFremanezumab-Vfrm16$11,539
EliquisApixaban16$10,365
Donepezil Hcl570$8,164
Zonisamide230$7,864
Carbidopa-LevodopaCarbidopa/Levodopa265$7,143
Lacosamide38$6,094
Memantine Hcl243$4,660
Propranolol Hcl ErPropranolol Hcl137$4,520
Primidone192$4,197

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$433$81,01911 claims
PfizerNurtec Odt, Eliquis$536$60,01760 claims
AbbVieQulipta, Ubrelvy$2,476$56,72553 claims
Upsher-smith Laboratories LLCTopiramate$40$1,331103 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 381 neurology providers in Missouri.

Other neurology in Saint Louis

See the full list for Missouri →

Where these figures come from

Is this you, or does something look wrong? →